neurotoxicity and mechanisms of induced hyperexcitability

More documents

Recommendations

Info

cysteine thiolactone (5.5 mmol/kg, i.p.). Nitro indazole isan inhibitor of neuronal nitric oxide synthase that attenuatespilocarpine-induced seizures (49). NO has been shownto modulate NMDA receptor activity by interacting withthe –SH group of its redox modulatory site via S-nitrosylation.This modification results in the downregulation ofthis receptor complex (19) and prevents the neurotoxic effectsof an excessive Ca 2+ influx during homocysteine inducedoverstimulation of NMDA and mGluRs I receptors.In addition, Kim et al. (50) demonstrated that NO ameliorateshomocysteine’s adverse effects of S-nitrosylationin cultured rat cortical neurons. Moreover, NO inducesa reduction of glutamate by activation of glial cells. Manyexperimental studies have demonstrated co-localisation ofNOS and GABA and have suggested that basal NO levelsinduce a depression of inhibition, while high concentrationsof NO increase GABA release. In contrast to homocysteine,which increases oxidative stress by the productionof reactive oxygen species, NO can act as a neuralprotector. This neuroprotective property is due to theformation of S-nitroso-L-glutathione, which is an antioxidantand NO scavenging molecule (51). However, therole of NO in epileptogenesis has been studied in differentexperimental models and reported results are highlycontradictory. Namely, the proconvulsive role of NO hasbeen demonstrated in the lindane model of convulsionsand several others (52). Thus, it seems that the activityof NO depends on the animal strain, the seizure modelemployed and the type and dose of drugs used in order tomodify cerebral NO levels.Furthermore, it has been demonstrated that when L-arginine is applied alone, it significantly increases the activityof Na + /K + -ATPase activity in the hippocampus, thecortex and the brain stem. However, when L-arginine is appliedprior to D,L homocysteine thiolactone (8 mmol/kg),this completely reverses its inhibitory effect (48). The sameholds true for its effects on Mg 2+ -ATPase activity in the ratcortex and the brain stem. L-NAME increases Na + /K + -AT-Pase activity in the cortex and the brain stem but not in thehippocampus. When L-NAME was administered prior tohomocysteine thiolactone (5.5 mmol/kg), it increased theactivity of both Na + /K + -ATPase and Mg 2+ -ATPase in therat cortex and the hippocampus.Changes in total spectral power density after ethanolalone and together with D,L-homocysteine thiolactone inadult rats were examined (53). Recording electrical activityfrom the brain represents a measure of both brain functionand dysfunction. Ethanol is used as a social substance and isthe second most widely used psychoactive substance in theworld after caffeine. The influence of ethanol on the centralnervous system depends on the dose, drinking pattern, toleranceand other factors. While chronic ethanol consumptionis followed by a series of seizures during the withdrawal period,acute ethanol intake exerts mainly inhibitory effects onthe CNS and is usually associated with an increase of seizurethreshold (54). Rasic-Markovic et al. (53) found that ethanol’saction on electrographic pattern is biphasic, which is characterisedby potentiation of epileptiform activity in one doserange and depression in another one. Low ethanol doses causingeuphoria and behavioural arousal are associated with desynchronisationof the EEG, decreases in the mean amplitudeand increases in theta and alpha activity. In addition, ethanolincreases mean total spectral power density 15 min and 30min after administration. Ethanol affects voltage-gated ionchannels, second messenger systems and a variety of differentneurotransmitter systems such as glycine, acetylcholineas well as monoamines and neuropeptides systems (55). Twomajor amino acid neurotransmitter systems, GABA and glutamate,as well as aspartate are affected by ethanol. Acute administrationof ethanol inhibits NMDA-induced Ca2+ influx,cyclic GMP production, neurotransmitter release and reducesNMDA-evoked neurotoxicity (56, 57).Pre-treatment with MK-801, which is a NMDA receptorantagonist, showed a tendency to reduced the incidenceof convulsions, latency to the first seizure onset and theseverity of seizure episodes; however, there was no statisticalsignificance when compared to the D,L-homocysteinethiolactone treated group. Nevertheless, the median numberof seizure episodes was significantly decreased by MK-801 when compared to the D,L-homocysteine thiolactonetreated group. On the other hand, ifenprodil, which is anothertype of NMDA receptor antagonist, decreased thelatency to the first seizure onset and increased the mediannumber of seizure episodes. The majority of seizure episodesin the ifenprodil (72.1%) and MK-801 (73.1%) groupswere significantly different compared to the D,L-homocysteinethiolactone treated group (36.0%). Our findingssuggest that D,L-homocysteine thiolactone induces seizuresthrough the stimulation of NMDA receptors in thecentral nervous system but other mechanisms (i.e., NOsignalling) may also be involved (58).Finally, limited data exist in the literature regarding theeffects of homocysteine and D,L-homocysteine thiolactoneon the activity of the acetylcholinesterase (AChE) enzymein the blood, but practically no data exist regarding the influenceof these compounds on this enzyme in the brainand heart. Recent results showed a significant reduction inAChE activity in all tissues obtained from rats treated withD,L-homocysteine thiolactone compared to the enzymeactivity of the control group. In addition, these results alsoshowed that the blood enzyme activity was the lowest (12%)after treatment, while the enzyme activity was slightly higherin the brain (27.8%) and heart samples (86.3%). Therefore,it was concluded that D,L-homocysteine thiolactone significantlyinhibited AChE activity in the heart and brain tissuebut not in the blood of the rat (59).Overall, these studies clearly demonstrate that acute administrationof homocysteine and especially D,L-homocysteinethiolactone elicit seizures in adult rats, affect neuronal activity,EEG recordings and behavioural responses. These effectshave been linked to the stimulation of NMDA receptors, inhibitionof the Na + /K + -ATPase, inhibition of AChE activity andthe functional involvement of NO during D,L-homocysteinethiolactone induced seizures in adult rats.7
ACKNOWLEDGEMENTSThis work was supported by the Ministry for Scienceand Technological Development of Serbia, Grant No.175032 and Grant No. 175043.REFERENCES1. Miller JW, Nadeau MR, Smith D, Selhub J. VitaminB-6 deficiency vs. folate deficiency: comparison of responsesto methionine loading in rats. Am J Clin Nutr1994; 59: 1033–39.2. Mato JM, Lu SC. Homocysteine, the bad thiol. Hepatology2005; 41: 976-79.3. Chwatko G, Jakubowski H. The determination of homocysteinethiolactone in human plasma. Anal Biochem2005; 15: 271-7.4. Obeid R, Herrmann W. Mechanisms of homocysteineneurotoxicity in neurodegenerative diseases with specialreference to dementia. FEBS Lett 2006; 580: 2994-05.5. Jakubowski H. Homocysteine is a protein amino acid inhumans.Implications for homocysteine-linked disease.J Biol Chem 2002; 277: 30425–28.6. Jakubowski H. The pathophysiological hypothesis ofhomocysteine thiolactone-mediated vascular disease. JPhysiol Pharmacol 2008; 59: 155–67.7. Syardal A, Refsum H, Ueland PM. Determination of invivo protein binding of homocysteine and its relation tofree homocysteine in the liver and other tissues of therat. J Biol Chem 1986; 261: 3156–63.8. De Bree A, Verschuren WMM, Kromhout D, KluijtmansLAJ, Blom HJ. Homocysteine determinants andthe evidence to what extent homocysteine determinesthe risk of coronary heart disease. Pharmacol Rev 2002;54: 599–18.9. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia:an independent risk factor for vasculardisease. N Engl J Med 1991; 324: 1149– 55.10. Troen AM. The central nervous system in animal modelsof hyperhomocysteinemia. Prog NeuropsychopharmBiol Psych 2005; 29: 1140-51.11. Zou CG, Banerjee R. Homocysteine and redox signaling.Antioxid Redox Signal 2005; 7: 547-559.12. Mitrovic V, Djuric D, Petkovic D, Hamm C. Evaluation ofplasma total homocysteine in patients with angiographicallyconfirmed coronary atherosclerosis: possible impacton therapy and prognosis. Perfusion 2002; 15: 10-19.13. Rieth A, Dill T, Deetjen A, Djuric D, Mitrovic V. Effectsof homocysteine-lowering therapy on endothelial function,carotid wall thickness and myocardial perfusion.Acta Facultatis Medicae Naissensis 2006; 23: 179-184.14. Djuric D, Vusanovic A, Jakovljevic V. The effectsof folic acid and nitric oxide synthase inhibition oncoronary flow and oxidative stress markers in isolatedrat heart. Molecular and Cellular Biochemistry 2007;300(1-2): 177-183.15. Djuric D, Jakovljevic V, Rasic-Markovic A, Djuric A,Stanojlovic O. Homocysteine, folic acid and coronaryartery disease: possible impact on prognosis and therapy.Indian J Chest Dis Allied Sci 2008; 50: 39-48.16. Reis EA, Zugno AI, Zugno AI, et al. Pretreatment withvitamins E and C prevents the impairment of memorycaused by homocysteine administration in rats. MetabBrain Disease 2002; 17: 211-17.17. Wuerthele SE, Yasuda RP, Freed WJ, Hoffer BJ. The effectof local application of homocysteine on neuronalactivity in the central nervous system of the rat. Life Sci1982; 31: 2683-91.18. Finkelstein JD. The metabolism of homocysteine: pathwaysand regulation. Eur J Pediatr 1998; 157: S40–Z4419. Lipton SA, Rosenberg PA. Excitatory amino acids as afinal common pathway for neurological disorders. NEngl J Med 1994; 330: 613– 22.20. Kamath AF, Chauhan AK, Kisucka J, et al. Elevated levelsof homocysteine compromise blood-brain barrierintegrity in mice. Blood 2006; 107: 591–93.21. Hanyu N, Shimizu T, Yamauchi K, Okumura N, HidakaH. Characterization of cysteine and homocysteinebound to human serum transthyretin. Clin Chim Acta2009; 403: 70–75.22. Chigurupati S, Wei Z, Belal C, et al. The homocysteineinducibleendoplasmic reticulum stress protein counteractscalcium store depletion and induction of CCA-AT enhancer-binding protein homologous protein ina neurotoxin model of Parkinson disease. J Biol Chem2009; 284: 18323–33.23. Hucks D, Thuraisingham RC, Raftery MJ, Yagoob MM.Homocysteine induced impairement of nitric oxide-dependentvasorelaxation is reversible by the superoxidedismutase mimetic TEMPOL. Nephrol Dial Transpl2004; 19: 1999–05.24. Stanojlovic O, Zivanovic D, Susic V. N-methyl-D-asparticacid and metaphit-induced audiogenic seizures in ratmodel of seizure. Pharmacol Res 2000 42: 247–53.25. Stanojlovic O, Hrncic D, Racic A, Loncar–StevanovicH, Djuric D, Susis V. Interaction of delta sleep-inducingpeptide and valproate on metaphit audiogenic seizuremodel in rats. Cell Mol Neurobiol 2007; 27: 923- 32.26. Vucevic D, Hrncic D, Radosavljevic T, et al. Correlationbetween electroencephalographic and motor phenomenain lindane – induced experimental epilepsy in rats.Canad J Physiol Pharmacol 2008; 286: 173-17927. Mladenovic D, Hrncic D, Vucevic D, et al. Ethanol suppressedseizures in lindane-treated rats. Electroencephalographicand behavioral studies. J Physiol Pharmacol2007; 58:641-54.28. Sprince H, Parker CM, Josephs JA. Homocysteine-inducedconvulsions in the rat: Protection by homoserine,serine, betaine, glycine and glucose. Agents Actions1969; 1: 9-13.29. Perla-Kajan J, Twardowski T, Jakubowski H. Mechanismsof homocysteine toxicity in humans. Amino Acids2007; 32:561-72.8
Page 2 and 3: Editor-in-ChiefSlobodan JankovićCo
Page 4 and 5: EDITORIAL EDITORIJAL EDITORIAL EDIT
Page 6 and 7: pathologies could be a direct conse
Page 10: 30. Shandra AA, Godlevskii LS, Brus
Page 13 and 14: INTRODUCTIONSchizophrenia is a chro
Page 15 and 16: sisted of consecutive interruptions
Page 17 and 18: with the other rats. After a saline
Page 19 and 20: 23. Ellenbroek, B.A., Pre-attentive
Page 22 and 23: ORIGINAL ARTICLE ORIGINALNI NAUČNI
Page 24 and 25: 1 -The primary site fragmentation p
Page 26 and 27: in Table 2. The mass spectrum of DM
Page 28 and 29: can be fragmented after a few elect
Page 30 and 31: ORIGINAL ARTICLE ORIGINALNI NAUČNI
Page 32 and 33: B) Spontaneous modelsThe most frequ
Page 34 and 35: Mouse/rat model Phenotype Reference
Page 36: 40. Ehses JA, Lacraz G, Giroix MH,
Page 39 and 40: INTRODUCTIONCardiovascular diseases
Page 41 and 42: REFERENCES1. Parfrey PS. Cardiac di
Page 43 and 44: teens and premature soccer players
Page 45 and 46: floppy disc (3.5”), writ ten as W
Page 47: CIP - Каталогизација

neurotoxicity and mechanisms of induced hyperexcitability

Create successful ePaper yourself

Delete template?

Save as template?